B. Metzler seel. Sohn & Co. Holding AG Buys New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 16,103 shares of the company’s stock, valued at approximately $935,000.

Other large investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after acquiring an additional 176,803 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Keros Therapeutics in the 2nd quarter valued at approximately $1,118,000. Bank of New York Mellon Corp raised its holdings in Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after acquiring an additional 18,755 shares in the last quarter. SG Americas Securities LLC acquired a new position in Keros Therapeutics in the 2nd quarter valued at approximately $532,000. Finally, American Century Companies Inc. raised its holdings in Keros Therapeutics by 24.9% in the 2nd quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock valued at $13,626,000 after acquiring an additional 59,364 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $55.92 on Friday. The firm has a market cap of $2.27 billion, a PE ratio of -10.73 and a beta of 1.23. Keros Therapeutics, Inc. has a one year low of $27.31 and a one year high of $73.00. The stock’s 50 day simple moving average is $59.30 and its 200 day simple moving average is $52.21.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.33) EPS. As a group, equities analysts expect that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KROS. Bank of America dropped their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Guggenheim began coverage on Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price for the company. Scotiabank began coverage on Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a report on Friday. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.